Triomics raises $22 million to expand AI oncology workflows
Triomics pulled in $22 million to speed a cancer-care bottleneck: matching patients to trials. MSK says its platform can replace 45-minute manual chart reviews with cited trial matches.
Triomics has raised $22 million in Series B funding to push deeper into one of oncology’s most stubborn bottlenecks, matching patients to the right trials and preparing visits fast enough for busy clinics. Battery Ventures led the round as the company expands an AI platform built to automate data-heavy work that oncologists and administrative staff often still handle by hand.
The pressure point is easy to measure. Cancer records can stretch across years and pull in notes, scans, pathology reports and fax images, making it difficult to spot trial eligibility or assemble the right facts before an appointment. Memorial Sloan Kettering Cancer Center said manual pre-screening against its clinical trial portfolio can take up to 45 minutes per patient. Its collaboration with Triomics, announced on November 4, 2025 through MSK iHub and the Clinical Research Innovation Consortium, uses an AI-powered platform that analyzes records, identifies eligible trials and produces itemized rationales with source citations.
The clearest proof of traction is where the product is already in use. Triomics says it has deployments at Memorial Sloan Kettering, Mount Sinai and Yale Cancer Center, and says it serves academic and community cancer care providers as well as life sciences customers. A Y Combinator posting says the company is trusted by four of the top 10 Best Hospitals for Cancer by U.S. News, though it does not name them publicly. That matters because the real test for oncology AI is not whether it sounds sophisticated in a demo, but whether cancer centers will let it sit inside workflows where speed, traceability and accuracy are essential.
Triomics is also trying to build a broader safety culture around that use case. The company says it helped create the Collaboration for Oncology focused LLM Training, or COLT, with more than 20 NCI-designated cancer centers and Ci4CC, reflecting oncology’s caution that generative AI remains nascent in a zero-fail space. Its platform is built to screen upcoming appointments against a trial portfolio and deliver matches directly into provider workflows, while the MSK collaboration could later expand to decentralized clinical trials with satellite clinics and partner institutions across the New York tri-state area. Triomics had already raised $15 million in May 2024, a sign that this latest round builds on commercial momentum rather than an early bet.
This article was produced by Prism’s automated news system from verified source data, official records, and press releases, then run through automated quality and moderation checks before publishing. The system is built and supervised by the people who set the standards it runs under. Read our full AI policy.
Did this article answer your question?
